Editas Medicine and Radius Health Choose Mass Innovation Labs for Rapid Start and Operational Capabilities

Two new member companies pick Kendall Square facility for research and laboratory space

CAMBRIDGE, Mass.--()--Mass Innovation Labs, an accelerated commercialization space located in Kendall Square, announced today the arrival of two innovative biotechnology and biopharmaceutical companies into its Cambridge facilities. The latest member companies include Editas Medicine Inc., a leading genome editing company dedicated to treating patients with genetically defined diseases, and Radius Health, a science-driven biopharmaceutical company focused on developing new therapeutics in the areas of osteoporosis, oncology and endocrine-related diseases.

Both Editas Medicine and Radius Health took advantage of the rapid start up time for companies to move into Mass Innovation Labs – which in some cases can be as soon as two weeks – allowing them to begin working in the lab quickly while occupying only the space they need. Member companies can save as much as 30 percent at Mass Innovation Labs versus the cost of a traditional lease for comparable laboratory space.

“Highly innovative biopharmaceutical and life sciences companies like Editas Medicine and Radius Health are recognizing the value of utilizing space at Mass Innovation Labs to achieve their research and business goals,” said Amrit Chaudhuri, CEO and cofounder of Mass Innovation Labs. “Mass Innovation Labs is able to service companies at a variety of growth stages, from startups to well-established businesses, and we are thrilled to welcome these two companies that are looking to use our space to invest in resources that they truly need.”

Editas (Nasdaq:EDIT), with headquarters in Cambridge, raised over $200 million through a significant private financing in August 2015 and the successful completion of its initial public offering of common stock in February 2016. The company was founded by world leaders in genome editing with the mission of translating the promise of genome editing science into a broad class of transformative genomic medicines for patients.

“Mass Innovation Labs gave us the ability to expand our lab space quickly, allowing us to focus on our work in developing a novel class of genome editing therapeutics,” said Alexandra Glucksmann, Ph.D., COO of Editas Medicine. “This turn-key lab space allows us to invest in the resources that are right for Editas at this point in our company’s growth.”

Radius Health (Nasdaq:RDUS), located in Waltham, is committed to developing new therapeutics in the areas of osteoporosis, oncology and endocrine-related diseases. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) was submitted in the U.S. at the end of the first quarter of 2016. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women.

“Radius is committed to advancing our research through innovative R&D models and collaborations,” said Dr. Gary Hattersley, founder and Chief Scientific Officer of Radius Health. “Mass Innovation Labs’ operational model and existing infrastructure enables Radius to rapidly expand our scientific capabilities, and in particular to accelerate our osteoporosis and oncology-focused programs, in the world’s leading global biotechnology hub of Cambridge, MA.”

Since launching in May 2015, Mass Innovation Labs has entered into agreements with ten companies, including: Imagen Biopharma, Gritstone Oncology, WaveGuide, and TCR2.

For more information on Mass Innovation Labs, please visit www.massinnovationlabs.com or join us on Facebook, Twitter and LinkedIn.

About Mass Innovation Labs
Mass Innovation Labs embodies an ecosystem of innovators in its 124,000-square-foot first-class chemistry and biology space in the heart of Kendall Square. We provide comprehensive solutions for growing companies, including animal facilities, on-site CRO support, co-located CRO services and operational needs. Our goal is to reduce the time for teams to overcome hurdles in achieving milestones. For more information, please visit www.massinnovationlabs.com or join us on Facebook, Twitter and LinkedIn.

About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Contacts

For Mass Innovation Labs
Jeff Stoecker, 617-624-3424
MassInnovationLabs@racepointglobal.com

Release Summary

Mass Innovation Labs, an accelerated commercialization space located in Kendall Square, announced today the arrival of Editas Medicine Inc. and Radius Health into its Cambridge facilities.

Contacts

For Mass Innovation Labs
Jeff Stoecker, 617-624-3424
MassInnovationLabs@racepointglobal.com